This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 40 and 80
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.

Provided treatments

  • Drug: Roflumilast
  • Drug: Placebo
  • Drug: Salbutamol

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01313494. The sponsor of the trial is AstraZeneca and it is looking for 626 volunteers for the current phase.
Official trial title:
A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial